Onfi Patient Email: “Commercial Copay Assistance”
Subject line: Commercial Copay Assistance Sent on: 8/23/2018 at 9 AM From: Managing LGS Pre-header: Learn about the updates to our Commercial Copay Assistance Program
Emails
Rebinyn HCP Email: “3 important considerations regarding rFIX treatments”
Subject line: 3 important considerations regarding rFIX treatments Sent on: Aug 16, 2018 at 7AM From: Novo Nordisk Pre-header: Providing more for your patients with hemophilia B.
Novoeight HCP Email: “Meet Vaughn, who lives with hemophilia A”
Received: June 20, 2018 at 7:02 AM Subject: Meet Vaughn, who lives with hemophilia A From: Novo Nordisk
Aimovig Patient Email: A new treatment option is here
Rebinyn Email Program
Email 1, subject line 1: A new treatment option for your patients Sent on: Nov 11, 2017 at 10am EST Same email, resent: Email 1, subject line 2: FDA Approved for 2018: Rebinyn® (Coagulation Factor IX [Recombinant], GlycoPEGylated) Sent On: Jan 21, 2018 at 4pm EST Email 2 subject line: Now available: Rebinyn® (Coagulation Factor IX [Recombinant], GlycoPEGylated) Continue reading
Speak ENDO Email: Ready to up your endometriosis IQ?
Subject line: Ready to up your endometriosis IQ? Received on: March 27, 2018 at 9:30am From: SpeakENDO
Email to HCPs from NovoSeven RT: Would you recognize acquired hemophilia?
Subject line: Would you recognize acquired hemophilia? From: Novo Nordisk Received on: Mar 26, 2018 at 12:54pm
Humira Email to Patients: How to improve the conversation with your doctor
Humira Email to Patients: Clear up some questions about plaque psoriasis
Novoeight Email to HCPs: Are your patients affected by formulary changes?
